Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

AcuCort publishes November 2026 newsletter

Pharmaceutical company AcuCort has published its November 2026 newsletter. In this edition, the company highlights its recently signed exclusive licence and distribution agreement with Kye Pharmaceuticals in Canada and provides insight into the business development process behind AcuCort’s international partnership agreements.

 

 

 

 

Read the newsletter

https://bit.ly/4kYh7SP

 

Would you like to receive future newsletters directly in your inbox? Sign up here:

https://www.acucort.se/EN/media/subscribe/

 

 

For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: +46 (0)70 365 5400
E-mail: jonas.jonmark@acucort.com

 

About AcuCort AB (publ)

AcuCort has developed and is commercialising Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-established corticosteroid dexamethasone. The medicine has a new, patented and user-friendly dosage form and is intended for, among other uses, the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting associated with chemotherapy, and patients with COVID-19 who require supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway and Finland, where it is also marketed. AcuCort (ticker: ACUC) is listed on Spotlight Stock Market. For more information, visit www.acucort.se.


 

 

 

 

Datum 2026-11-18, kl 13:00
Källa Cision